Analysis of the risk factors for allograft vasculopathy in asymptomatic patients after cardiac transplantation
AUTOR(ES)
Bacal, Fernando, Veiga, Viviane Cordeiro, Fiorelli, Alfredo Inácio, Bellotti, Giovanni, Bocchi, Edimar Alcides, Stolf, Noedir Antonio Groppo, Ramires, José Antonio Franchini
FONTE
Arquivos Brasileiros de Cardiologia
DATA DE PUBLICAÇÃO
2000-11
RESUMO
OBJECTIVE: To study the influence of immune and nonimmune risk factors on the development of allograft vasculopathy after cardiac transplantation. METHODS: We studied 39 patients with a mean age of 46±12 years. The following variables were analyzed: weight (kg), body mass index (kg/m²), donor's age and sex, rejection episodes in the first and second years after transplantation, systolic and diastolic blood pressures (mmHg), total cholesterol and fractions (mg/dL), triglycerides (mg/dL), diabetes, and cytomegalovirus infection. The presence of allograft vasculopathy was established through coronary angiography. RESULTS: Allograft vasculopathy was observed in 15 (38%) patients. No statistically significant difference was observed between the two groups in regard to hypertension, cytomegalovirus infection, diabetes, donor's sex and age, rejection episodes in the first and second years after transplantation, and cholesterol levels. We observed a tendency toward higher levels of triglycerides in the group with disease. Univariate and multivariate analyses showed statistically significant differences between the two groups when we analyzed the body mass index (24.53±4.3 versus 28.11±4.6; p=0.019). CONCLUSION: Body mass index was an important marker of allograft vasculopathy in the population studied.
Documentos Relacionados
- What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy?
- New developments in the diagnosis and management of cardiac allograft vasculopathy.
- Indirect recognition of allopeptides promotes the development of cardiac allograft vasculopathy
- Regulation of human aortic endothelial cell-derived mesenchymal growth factors by allogeneic lymphocytes in vitro. A potential mechanism for cardiac allograft vasculopathy.
- Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation